Boryeong Pregabalin Capsule 75 mg
Pregabalin 75mg
Prescription medication
Boryeong Co., Ltd.
MFDS item code 202001270 · Approved 2020.02.21
This product's status changed to Expired on 2025.02.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy, applicable whether or not there are secondary generalized symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. Overall, this medication effectively supports management of various nerve-related disorders and pain.
This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration regimen. b: The supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12–17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so if any symptoms of depression or mood changes occur during treatment, you should immediately inform your healthcare provider. Patients who are allergic to any of the ingredients in this medication should not take it. Moreover, patients with genetically-based lactose intolerance should also avoid taking this medication. Diabetic patients may need to adjust the dosage of their blood sugar control medications due to weight gain. If symptoms of angioedema appear, the medication should be stopped immediately. Elderly patients should be cautious of the risk of falls due to dizziness or drowsiness, and they may experience vision changes such as blurred vision. If this medication is suddenly discontinued, withdrawal symptoms such as insomnia, headache, nausea, and anxiety may occur, so consultation with healthcare providers is recommended when stopping the medication. Due to the risk of drug abuse, patients with a history of drug abuse should take extra caution. Patients with impaired renal function may need to adjust the dosage of this medication. Patients with heart disease should use it cautiously, as there is an increased risk of central nervous system depression when taken with opioid analgesics. Patients with compromised respiratory function or elderly patients may be at risk for severe respiratory depression and should consult with their healthcare provider. In early pregnancy, there is a risk of congenital malformations in the fetus, so women who are pregnant or planning to become pregnant should discuss with their doctor before taking this medication. Lactating women should consider stopping breastfeeding or discontinuing the medication, as it may pass into breast milk. This medication can cause dizziness and drowsiness, so activities such as driving or operating dangerous machinery should be avoided after taking it. In case of overdose, symptoms such as confusion, drowsiness, depression may occur, and treatment such as hemodialysis may be necessary. Store this medication out of reach of children, and it is recommended not to transfer it to another container. If any unusual symptoms such as skin rash, fever, or facial swelling occur during treatment, the medication should be stopped immediately and the healthcare provider informed.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress. It is advisable to keep it in a cool place between 15 to 30 degrees Celsius.
A hard capsule with a light brown upper part and a white lower part, containing a white or light yellow powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 75mg
Prescription medication
Boryeong Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.